CSIMarket
 
Arca Biopharma Inc   (ABIO)
Other Ticker:  
 
 
Price: $1.8400 $0.01 0.546%
Day's High: $1.88 Week Perf: -3.16 %
Day's Low: $ 1.78 30 Day Perf: 2.22 %
Volume (M): 19 52 Wk High: $ 2.70
Volume (M$): $ 36 52 Wk Avg: $2.08
Open: $1.88 52 Wk Low: $1.74



 Market Capitalization (Millions $) 27
 Shares Outstanding (Millions) 14
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -5
 Cash Flow (TTM) (Millions $) -5
 Capital Exp. (TTM) (Millions $) 0

Arca Biopharma Inc


   Company Address: 10170 Church Ranch Way Westminster 80021 CO
   Company Phone Number: 940-2200   Stock Exchange / Ticker: NASDAQ ABIO
   ABIO is expected to report next financial results on February 23, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Mymd Pharmaceuticals Inc

Mymd Pharmaceuticals Inc's Troubling Third Quarter Earnings: A Bumpy Ride for Investors

During the past week, Mymd Pharmaceuticals Inc experienced a significant decline in its shares, dropping by -7.89%. This downward movement has further contributed to the company's already poor year-to-date performance, which now stands at -76.07%. Additionally, Mymd Pharmaceuticals Inc shares are currently trading only 7.6% above their 52-week low.
This decline in share value comes at a time when the In Vitro and In Vivo Diagnostic Substances industry is evaluating the third-quarter earnings of 2023. Specifically, MYMD, a key contributor to this industry, reported an operating loss of $-3.842588 million for the period between July and September 30, 2023. It is important to note that MYMD has not yet generated any revenue during this reporting season. However, market analysts anticipate additional revenue sources to emerge soon, given the current stage of the entity.

Oncocyte Corporation

Oncocyte Corporation's Revenue Surges in Q3 2023, but Profitability Remains Elusive



Oncocyte Corporation, a leading player in the In Vitro and In Vivo Diagnostic Substances industry, recently released its financial results for the third quarter of 2023. Despite reporting a significant increase in revenue compared to the same period last year, the company witnessed a widening of its losses. This article will outline the key facts from Oncocyte Corporation's financial results and provide context to better understand the company's performance in the industry.
Revenue Growth and Comparisons:
Oncocyte Corporation announced an impressive year-on-year revenue advancement of 946.341% in the third quarter of 2023, reaching $0.43 million. This growth significantly outperformed its industry peers, who reported an aggregated 11.10% top-line advance during the same period. However, it is important to note that the company's revenue deteriorated by -7.343% from the previous reporting season, where it recorded $0.46 million in revenue.

Volitionrx Limited

Volitionrx Limited's Stock Skyrockets, but Challenges Loom: A Closer Look at the Company's Financial Results and Future Prospects



Volitionrx Limited, a biomedical company that specializes in blood-based diagnostics, experienced a significant increase in its stock value over the past week and month. However, despite robust revenue growth, the company continues to face challenges. This article delves into Volitionrx Limited's recent financial results and analyzes how these factors may impact the company's future prospects.
Impressive Revenue Growth:
Volitionrx Limited reported a remarkable year-on-year revenue increase of 405.016% to $0.17 million in the most recent fiscal period. This surge indicates a strong demand for the company's blood-based diagnostic solutions. Such exponential revenue growth demonstrates a positive market reception of Volitionrx's products and services.

Navidea Biopharmaceuticals Inc

Navidea Biopharmaceuticals Inc Turns the Tide: Destroys Deficit with $0.02 Per Share Profit in Q3 2023!

Navidea Biopharmaceuticals Inc (NAVB) has recently reported its financial results for the fiscal time-frame of July to September 2023. While the company did incur losses of $-0.02 per share during this period, it is worth noting the significant improvement compared to a loss of $-0.25 per share in the same quarter last year. Furthermore, earnings per share fell from $0.12 per share in the previous quarter, indicating a slight setback.
Although the revenue remained stagnant at $0.00 million, it is important to recognize that this figure was also consistent with the previous year's comparable quarter. Additionally, the revenue remained unchanged sequentially, indicating stability in the company's financial performance.

Aspira Women S Health Inc

Aspira Women S Health Inc registers steady top-line growth in their recent fiscal period

Aspira Women's Health Inc, a leading healthcare company focused on women's health, recently released its financial results for the third quarter of 2023. The company reported a significant increase in the shortfall per share compared to the same period last year and the preceding reporting season. For the financial third quarter of 2023, AWH recorded a shortfall of $-0.48 per share, which is higher than the $-0.04 per share reported a year ago and the $-0.28 per share from the preceding reporting season.
In terms of revenue, Aspira Women's Health Inc experienced growth in comparison to the same reporting season a year ago, with a 6.998% increase, reaching $2.22 million from $2.07 million. However, the sequential revenue showed a deterioration of -11%, falling from $2.49 million in the previous reporting season.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com